Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Want to cut your energy bills? Here’s how five experts are doing it 
Rising U.S.-Iran Conflict Fuels Oil Market Volatility and Ceasefire Uncertainty 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Gold Prices Slip Amid Iran Tensions and Fed Chair Uncertainty 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
US-Iran Peace Talks Fuel Market Optimism Amid Ongoing Tensions 
Booked to travel through the Middle East? Here’s why you shouldn’t cancel your flight 
Yes, government influences wages – but not just in the way you might think 
Oncologica has launched its Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer.
A significant proportion of men, particularly those people who develop aggressive life-threatening prostate cancer at a relatively early age, can now be identified as a consequence that they carry inherited abnormal disease-causing genes.
The family of inherited prostate cancer-causing genes is all involved in a process called DNA damage repair (DDR) which plays a critical role in ensuring that the DNA in your cells is maintained in a healthy state.
An inherited abnormality in any of these DDR genes predisposes men to the development of early aggressive prostate cancer. Notably, survival among men with faulty DNA repair genes is half that of men with normal DDR genes.
The new genetic Prostatefocus genetic screening test uses a simple saliva self-sample collection kit. Men who test positive can then benefit from regular checks, blood tests, and lifestyle preventative measures.
Dr. Marco Loddo, co-owner and scientific director at Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, said that prostate cancer tends to grow slowly without symptoms, so men often present late with an advanced incurable disease.
Prostate cancer is more treatable when caught early so screening tests can help identify an individual at high risk of developing the disease so regular checks can take place.
The Prostatefocus test is available via Oncologica’s nationwide specialist medical healthcare providers who conduct a pre-test consultation explaining how the test works and the implications of any results.
